37.03

2.27% -0.86

After Hours: 37.03

Kiniksa Pharmaceuticals International Plc (KNSA)

Overview News Price History Option Chain Financials Discussions Forecast

Kiniksa Pharmaceuticals International Plc stock is traded at $37.03, with a volume of 346.97K. It is down -2.27% in the last 24 hours and down -0.19% over the past month. Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.

Previous Close:

$37.89

Open:

$38.21

24h Volume:

346.97K

Relative Volume:

0.70

Market Cap:

$1.61B

Revenue:

$384.10M

Net Income/Loss:

$-9.07M

P/E Ratio:

-264.50

EPS:

-0.14

Net Cash Flow:

$11.10M

1W Performance:

-3.29%

1M Performance:

-0.19%

6M Performance:

+91.77%

1Y Performance:

+39.42%

1-Day Range:

$37.00

$38.29

1-Week Range:

$37.00

$39.43

52-Week Range:

$17.82

$39.43

Kiniksa Pharmaceuticals International Plc Stock (KNSA) Company Profile

Name

Kiniksa Pharmaceuticals International Plc

Sector

Healthcare (1142)

Industry

Drug Manufacturers - Specialty & Generic (85)

Phone

(781) 431-9100

Address

23 OLD BOND STREET, FLOOR 3, LONDON

Employee

315

Twitter

@kiniksa

Next Earnings Date

2024-10-29

Latest SEC Filings

KNSA's Discussions on Twitter

Compare KNSA with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
KNSA Kiniksa Pharmaceuticals International Plc	37.03	2.81B	384.10M	-9.07M	11.10M	-0.14
ZTS Zoetis Inc	142.26	62.54B	9.39B	2.62B	2.22B	5.8121
TAK Takeda Pharmaceutical Co Adr	13.72	43.30B	29.96B	957.25M	4.77B	0.2956
HLN Haleon Plc Adr	9.08	40.08B	14.26B	1.98B	2.47B	0.4327
TEVA Teva Pharmaceutical Industries Ltd Adr	20.02	22.98B	16.70B	-157.13M	1.19B	-0.1446
UTHR United Therapeutics Corp	440.06	19.90B	3.08B	1.24B	1.07B	25.61

Kiniksa Pharmaceuticals International Plc Stock (KNSA) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Sep-29-25	Initiated	TD Cowen	Buy
Mar-13-25	Initiated	Citigroup	Buy
Sep-13-24	Initiated	Jefferies	Buy
May-03-24	Initiated	Wells Fargo	Overweight
Jun-29-20	Reiterated	BofA Securities	Buy
Apr-01-20	Initiated	BofA/Merrill	Buy
Mar-11-19	Initiated	Barclays	Overweight
Dec-12-18	Reiterated	Wedbush	Outperform
Jun-19-18	Initiated	JMP Securities	Mkt Outperform

View All

Kiniksa Pharmaceuticals International Plc Stock (KNSA) Latest News

09:52 AM

KNSA: Wedbush Maintains Outperform Rating, Raises Price Target t - GuruFocus

09:52 AM

08:13 AM

Wedbush Lifts Price Target on Kiniksa Pharmaceuticals International to $44 From $38, Keeps Outperform Rating - MarketScreener

08:13 AM

Oct 10, 2025

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Reaches New 1-Year HighStill a Buy? - MarketBeat

Oct 10, 2025

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Receives Consensus Recommendation of “Moderate Buy” from Brokerages - Defense World

Oct 10, 2025

Kiniksa Pharmaceuticals International, plc (NASDAQ:KNSA) Receives Consensus Recommendation of "Moderate Buy" from Brokerages - MarketBeat

Oct 10, 2025

Oct 09, 2025

Robeco Institutional Asset Management B.V. Buys New Position in Kiniksa Pharmaceuticals International, plc $KNSA - MarketBeat

Oct 09, 2025

Oct 08, 2025

Kiniksa Pharmaceuticals International (NASDAQ:KNSA) Rating Lowered to "Hold" at Zacks Research - MarketBeat

Oct 08, 2025